RadioImmunotherapy for adenoid cystic carcinoma: a single-institution series of combined treatment with cetuximab by Jensen, Alexandra D et al.
RESEARCH Open Access
RadioImmunotherapy for adenoid cystic
carcinoma: a single-institution series of
combined treatment with cetuximab
Alexandra D Jensen
1*, Jürgen Krauss
2, Wilko Weichert
3, Jürgen Debus
1, Marc W Münter
1
Abstract
Background: Local control in adjuvant/definitive RT of adenoid cystic carcinoma (ACC) is largely dose-dependent.
However, some clinical situations do not allow application of tumouricidal doses (i.e. re-irradiation) hence radiation
sensitization by exploitation of high endothelial growth factor receptor (EGFR)-expression in ACC seems beneficial.
This is a single-institution experience of combined radioimmunotherapy (RIT) with the EGFR-inhibitor cetuximab.
Methods: Between 2006 and 2010, 9 pts received RIT for advanced/recurrent ACC, 5/9 pts as re-irradiation.
Baseline characteristics as well as treatment parameters were retrieved to evaluate efficacy and toxicity of the
combination regimen were evaluated. Control rates (local/distant) and overall survival were calculated using
Kaplan-Meier estimation.
Results: Median dose was 65 Gy, pts received a median of 6 cycles cetuximab. RIT was tolerated well with only
one °III mucositis/dysphagia. Overall response/remission rates were high (77,8%); 2-year estimate of local control
was 80% hence reaching local control levels comparable to high-dose RT. Progression-free survival (PFS) at 2 years
and median overall survival were only 62,5% and 22,2 mo respectively.
Conclusion: While local control and treatment response in RIT seems promising, PFS and overall survival are still
hampered by distant failure. The potential benefit of RIT with cetuximab warrants exploration in a prospective
controlled clinical trial.
Introduction
Adenoid cystic carcinomas are rare tumours mostly
of the head and neck and account for approximately
10-15% of malignant salivary gland tumours [1]. They are
characterised by a rather slow growth pattern but also
perineural spread and a high propensity for haematogen-
ous metastases. Standard treatment so far consists of
complete surgical resection followed by adjuvant irradia-
tion in case of risk factors (i.e. close margins, perineural
invasion, extensive primary tumor (T3, T4) or high-grade
histology) [2-4].
Local control in this disease could already be improved
by adjuvant radiation, the introduction of high-precision
RT techniques (i.e. FSRT and/or IMRT) with consecutive
dose escalation, and last but not least high-LET RT. To
achieve local control, radiation doses of >60 Gy or even
66 Gy are recommended [5-8].
Initial local control rates combined IMRT plus C12
heavy ion boost to a total dose of 72 GyE were 78% at 4
years [9]. Recent updates including all patients treated
at the Gesellschaft für Schwerionenforschung (GSI)
Darmstadt between 1997 and 2008 even yielded a local
control rate of 82% at 5 years [10,11]. Therefore the
combination of IMRT and carbon ion boost shows com-
parable or even superior control rates to neutron RT
[12,13] without increase of late toxicity and subsequent
morbidity consistent with outcomes reported by Mizoe
et al [14]. Therefore, IMRT plus C12 boost has been
accepted as a standard in Germany whenever available.
Albeit progress has been made by the introduction of
particle therapy in the treatment concept of adenoid cys-
tic carcinoma, local control rates still leave room for
improvement. With the successful introduction of com-
bination regimen in squamous cell carcinoma of the head
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not only in local control but also in overall survival,
investigation of this approach was obvious in adenoid
cystic carcinoma hoping for further improvement of local
control and higher response rates of bulky tumours.
Radiochemotherapy in the treatment of malignant sali-
vary gland tumors (MSGT) however, has not evolved
beyond the phase II-stage or retrospective analysis of
very heterogeneous treatment regimen [15-18] into a
treatment standard so far as results have been more or
less inconclusive.
Immunostaining of surgical specimen however [19],
could show over-expression of EGFR in adenoid cystic
carcinoma in high percentages hence implying use of
targeted therapies as potential alternative [19,20] to
comparatively toxic chemotherapy regimen commonly
used in recurrent or metastatic adenoid cystic carci-
noma since the mid 80-ies [21-24]. Despite the initial
euphoria, treatment results have so far failed to impress:
no objective response in recurrent or metastatic adenoid
cystic carcinoma could be shown in any of the trials
[25-27] although prolonged disease stabilization was
observed in the reported series [26,27].
Since the publication of combined radioimmunother-
apy with the EGF receptor antibody cetuximab in
SCCHN of the Bonner trial in 2006 [28,29] though,
application of these drugs in adenoid cystic carcinoma
seemed feasible in view of potential increase of radiation
sensitivity and - albeit modest - systemic activity given
the relatively mild toxicity profile of EGFR antibodies.
Hence, we would like to present our experiences in
combined radioimmunotherapy of adenoid cystic carci-
noma with cetuximab.
Methods
In an individual approach patients received radioimmu-
notherapy with cetuximab for advanced or recurrent
adenoid cystic carcinoma between 01/2006 and 06/2010.
Baseline characteristics as well as treatment parameters
were retrieved to evaluate efficacy and toxicity of the
combination regimen were evaluated.
Indication
Radioimmunotherapy for adenoidcystic carcinoma not
representing a therapeutic standard, medical indication
was highly individual and made in interdisciplinary con-
sensus only in cases where applicable radiation doses
were deemed insufficient for reasonable tumour control.
Given the fact carbon ion treatment was only available
three times a year for a very limited number of patients,
this series includes patients in need of immediate treat-
ment due to rapid tumour progression or locoregional
relapse after prior RT. Sufficient dose prescription (>70
Gy) was not possible in all of these cases either because
of proximity/involvement of critical structures or prior
RT, hence the idea was to increase efficacy of radiation
therapy by combined radioimmunotherapy usually
accompanied with only mild toxicity. Rationale for the
proposed treatment was extensively discussed and deci-
sions made in accordance with the patients.
5/9 pts hade undergone prior RT (median dose: 58 Gy,
range 50,4 - 62 Gy) with a median time interval of
57 months for treatment for adenoidcystic carcinoma.
Four pts received radioimmunotherapy as part of their
primary treatment but showed extensive tumour mass
directly adjacent to or involving critical structures. 8/9
pts received IMRT (2 pts as tomotherapy, 6 pts in step
and shoot technique), 1 pt received combined IMRT plus
C12-boost due to rapid postoperative local progression.
Histomorphologic evaluation and immunohistochemistry
The histomorphological diagnosis of adenoid cystic car-
cinoma was confirmed in all cases by a board certified
pathologist with a special expertise in head and neck
pathology. For immunohistochemistry 5 μm paraffin
sections were cut. Detection of EGFR was performed
with the EGFR pharm Dx kit by DAKO (K1492) accord-
ing to the manufacturer’s instructions. Staining was
scored as positive if any membranous positivity was
observed, however, all investigated cases showed strong
membranous positivity in a considerable number of
tumor cells (Figure 1a/b).
Radiation therapy
Immobilization/planning examinations
Patients were immobilized using individual scotch cast
or thermoplastic head masks with thermoplastic
shoulder fixation. Planning examinations consisted of a
planning CT scan (3 mm slice thickness) with the
patient positioned in the individual fixation device and
contrast-enhanced MRI for 3 D image correlation.
Target volumes: primary (photon) RT
Target delineation was carried out based on planning
CT and MRI scan. CTV1 included the macroscopic
tumor/prior tumor bed with a margin of 2 mm with
special focus on the R2/R1-area as well as respective
neural pathways to the base of skull (cave: perineural
invasion and skip lesions).
CTV2 included CTV1 with generous safety margin
along typical pathways of spread (if possible safety mar-
gin of about 5 cm) depending on the anatomical relation-
ship of adjacent structures. In particular, neurovascular
sheaths and locoregional ipsilateral nodal levels were also
included in the CTV2.
Target volumes: re-irradiation
For patients who had already undergone a course of
prior radiotherapy, the treatment volume was strictly
limited to the gross tumour volume and did not include
Jensen et al. Radiation Oncology 2010, 5:102
http://www.ro-journal.com/content/5/1/102
Page 2 of 8elective nodal levels. Doses of were highly individualised
but aimed at 50 - 60 Gy re-irradiation in 2 Gy/fraction
[30] depending on elapsed time since the first course of
RT and prior RT-dose.
Target volumes: combined IMRT + carbon ion boost
CTV1 (carbon ion boost) included the macroscopic
tumor/prior tumor bed with special focus on the R2/R1-
area as well as respective neural pathways to the base of
skull (cave: perineural invasion and skip lesions). PTV1
consists of a 3 mm margin around the CTV1 but does
not extend into critical organs at risk (i.e. brain stem,
spinal cord).
Treatment is given at the HIT (Heidelberg ion therapy
centre) after inverse treatment planning in active beam
application (raster-scanning method).
CTV2 included CTV1 with safety margins along typi-
cal pathways of spread. Only ipsilateral nodal levels (II
and III) are included, however, in case the primary
tumor is/was located at midline or crossing midline,
bilateral nodal levels II and III are covered. In case there
is pathological lymph node involvement, additional
nodal levels were covered as indicated. CTV2 also
encompassed the complete surgical operational area.
The CTV2 also takes account for set-up variations,
hence corresponds to the PTV2 (CTV2 = PTV2).
Immunotherapy
Cetuximab was administered as 400 mg/m2 body sur-
face loading dose 7 days prior to RT-treatment start
after administration of anti-histamines (dimetindene)
and corticosteroids (dexamethasone).
Weekly administrations of Cetuximab 250 mg/m2
body surface followed for the duration of radiotherapy.
Analysis
Treatment response was analysed 6 wks post completion
of RIT (first follow-up) and at each available follow-up
(best response) according to RECIST criteria [31] based
on available follow-up scans (CT or MRI) and clinical
examinations. Treatment outcome (locoregional, distant
and overall progression-free survival as well as overall
survival) was evaluated using higher non-parametric sta-
tistics (Kaplan-Meyer survival analysis) with the software
xlstat 2010. Progression-free survival was defined as the
time from start of combined radioimmunotherapy until
the first event (i.e. locoregional relapse, distant metas-
tases, death). Similarly, overall survival was calculated
from start of radioimmunotherapy until death from any
cause.
Results
Nine pts with adenoid cystic carcinoma receiving com-
bined radioimmunotherapy with cetuximab were identi-
fied. Median follow-up is 12,5 months [1,2 - 29,6 mo].
Tumours were mostly located near or at the base of
skull (epipharynx, pterygopalatine fossa, skull base). All
patients had a macroscopically visible tumour mass, all
but one T4 tumours (patient characteristics see table 1).
EGFR expression analysis was available in 8/9 pts (all of
them with at least moderate or high expression rates),
specimen for one pt were unfit for EGFR analysis.
Median dose applied was 65 Gy (total) and 50,4 Gy in
pts receiving the second course of radiation (median
cumulative dose 111,2 Gy) after a median interval of
63,7 months between the two courses (table 2). All pts
Figure 1 ACC and EGFR expression. (A) Histology of an adenoid cystic carcinoma (H&E stain). (B) Strong membranous expression of EGFR in
the majority of tumor cells of the same tumor (EGFR immunohistochemistry). Magnification ×200.
Table 1 patient characteristics
patient characteristics
median age 56 a [40 - 77]
tumour localisation
Epipharynx 2 pts
base of skull 2 pts
Fossa pterygopalatina 3 pts
Maxilla 1 pt
tuba auditiva 1 pt
tumour stage T4 8 pts
T3 1 pt
no nodal involvement 9 pts
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(8/9pts) or as combined treatment with carbon ion
boost (1/9 pts). Prior RT in the 5 cases with re-irradia-
tion was carried out using IMRT (3 pts), stereotactic
single fraction only (1 pt) and 3 D conventional (1 pt).
All patients completed the treatment as planned; there
were no treatment interruptions. A median of 6 cycles
cetuximab [4 - 8 cycles] (excluding loading dose) were
applied. Treatment was tolerated well without any cases
of allergic reactions and only one case of CTC °III toxi-
city (mucositis °III leading to temporary feeding tube
dependence). 8/9pts developed acneiforme skin reac-
tions °I/II, 7/9 pts radiodermatitis °I/II and mucositis
°I/II (table 3). In the 7 pts with follow-up available,
acute reactions were completely resolved at first follow-
up, there were no treatment-related late effects.
At first follow-up 8/9 pts (88,9%) showed good partial
remissions. 1 pt died prior to the first f/u (6 wks post
RT) due to tumor bleeding. (table 4). On further f/u,
6/7pts stayed locally controlled. Figure 2(a/b) shows the
pretherapeutic MRI scan for a patient with large ACC
extending from the optic canal to the pterygoid muscles.
The applied IMRT treatment plan using a simultaneous
integrated boost concept and the corresponding DVH
are shown in Figures 3a/b and 4. 66 Gy were prescribed
to the median of CTV1. However, impaired coverage
needed to be accepted in order to spare the left optic
nerve. This patient is still locally controlled 21/2 years
post treatment, one f/u scan showing good PR is
depicted on Figure 5 (a/b). Another pt actually showed
a complete remission on further f/u corresponding to a
2-year local control rate of 80% (Figure 6). 1 pt
developed a regional relapse outside the re-RT field 10
mo post re-RT, 1 pt developed local, locoregional, and
distant relapse (pulmonary and hepatic metastases).
Another patient has so far stayed locally controlled but
did develop bone metastases, distant control and PFS at
2 years are 62,5% (Figures 7+8). Four pts received
further treatment (2 pts with chemotherapy for local
progression (carboplatin/vinorelbine, 1 pt) and distant
failure (paclitaxel, 1 pt), 1 pt received photodynamic
therapy for contralateral progression (out-of field), 1 pt
received further radiation for bone metastases). Four
patients are deceased as of July 2010 due to disease pro-
gression, hence overall survival at 2 years is only 25%
and corresponding to disease-specific survival (Figure 9).
Discussion
In SCCHN, combination therapy with the EGFR-anti-
body cetuximab yielded comparable results to chemora-
diation regimen on retrospective comparisons [29,32]
without increase of toxicity - except acneiforme skin
reactions - and has therefore raised interest for this
combination also in other histologies. Analyses on ade-
noid cystic carcinoma surgical specimen showed high
rates of EGFR and c-kit expression, hence potential tar-
gets for biological agents [19,20]. Faced with limitations
in dose prescription in the presented cases, we saw the
chance to exploit radio-sensitizing potential of the
EGFR- antibody cetuximab to potentially improve these
patients’ outcome despite necessary compromises on
dose and target volume coverage at the cost of very low
toxicity. Consistent with the data by Bonner et al
[28,29,32], combined radioimmunotherapy with cetuxi-
mab was tolerated well and without any major, treat-
ment-related side effects despite one case of °III
mucositis and consecutive dysphagia. Considering the
extent and localisation of the target volume, this would
also have been expected in single-modality RT.
Treatment response with approx. 78% in all pts (7/9
pts) and 100% in pts with follow-up available as well as
local control (80% @2a) were comparatively high despite
the fact 5/9 pts (55,6%) received therapy as re-irradia-
tion. So far, published data report local control rates in
Table 2 treatment
radiotherapy median min max
(overall)
median dose 65 Gy 39,6 Gy 72,8 Gy
(re-RT)
median dose 50,4 Gy 39,6 Gy 69,9 Gy
median cumulative dose 111,2 Gy 97,6 Gy 130,5 Gy
median interval between RTs 63,7 mo 11,3 mo 91,1 mo
Table 3 observed toxicity
acute toxicity CTC v3.0
I/pts II/pts III/pts
acneiforme dermatitis 44
radiogenic erythema 52
mucositis 25 1
dysphagia 30 1
xerostomia 2
Table 4 treatment response
treatment response @ 6-8 wks post Rt further f/u
total PR 7 pts 6 pts
CR 1 pt
dna 2 pts 2 pts
re-RT PR 4 pts 2 pts
CR 0 1 pt
PD 0 1 pt
dna 1 pt 1 pt
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IMRT and carbon ion boost [9], between 75 - 100% for
particle therapy including neutrons [12,13,33], and
between 24,5% and 82% in at least R1 resected tumours
with up to 62% in large primary or R2-resected disease
[4,7,13,34]. While our median local control has not been
reached, the actuarial local control in our series was
80% at 2 years, hence slightly higher than in the pre-
viously published IMRT-series (local control of 75% at 2
years and 38% at 4 years [34]) and comparable to the
above mentioned carbon ion results [9]. Considering a
median overall survival of 20 months, it is, however, not
possible to extrapolate expected local control rates. As
reported by the groups of Chen and Garden [6-8], local
control was largely dependent on applied dose, hence
doses of >60-66 Gy are recommended. Despite neces-
sary compromises on target volume coverage and or
dosage, all of our patients showed at least a partial
remission on their follow-up scans, hence, response
rates of the combined approach are encouraging.
W h i l ew eh a v eo n l ys e e no n ec a s eo fl o c a lf a i l u r ei n
this cohort, distant failure seemed much higher (distant
ctrl @2a: 62,5%), hence the progression-free survival
rate is largely influenced by the rate of distant failure.
Overall survival in this series with 25% at 2 years was
disappointing, however, none of the pts in previous ser-
ies had undergone re-RT or been treated for disease
recurrence, therefore worse outcomes might be expected
Figure 2 Initial, contrast-enhanced MRI of a large adenoid cystic carcinoma extending from the left pterygoid muscles (a) into the
cavernous sinus and left orbit (b).
Figure 3 IMRT treatment plan applying an integrated boost concept; dose distribution pterygoid muscles (a) and cavernous sinus/left
orbit (b); 100% corresponding to 66 Gy; CTV1 receives a median of 66 Gy, CTV2 was prescribed 54 Gy.
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ease. Overall survival being a function of distant failure
is a finding consistent with our previous experience and
other groups [9,12,13,34-36], therefore, a lot of research
has been directed at improvement of systemic control in
adenoidcystic carcinoma. Faced with the sometimes very
slow progression, interest in targeted therapies for sys-
temic treatment of MSGT and accompanying mild toxi-
city profile arose very early on. Based on pathological
findings of high EGFR-expression in adenoid cystic car-
cinoma surgical specimen [19], there have been various
phase I-II trials using EGFR antibodies or tyrosine
kinase inhibitors in locally recurrent/metastatic pts
[25-27]. However, though prolonged disease stabilization
was observed, no objective response could be shown. It
might be worth noting that initial experiments with
cetuximab and radiation in various cell lines were in
fact able to establish a synergistic effect of the two treat-
ment components resulting in increased efficiency of the
combination than either single modality [37,38]. Hence,
the fact cetuximab might not have vast impact in meta-
static disease does not preclude efficiency of the combi-
nation regimen. Further individualization of treatment
will require identification of predictors for metastatic
spread in adenoid cystic carcinoma in order to intensify
the systemic treatment component for these patients.
Patients with localized disease however, may profit from
more aggressive local treatment procedures such as
combined with carbon ion therapy as proposed here.
Conclusion
In Summary, radioimmunotherapy with cetuximab was
tolerated well and yielded promising response and local
control rates. Overall survival in this series was com-
paratively low and it remains unclear whether cetuximab
or any other EGFR-antibody/tyrosine kinase inhibitor
may reduce the rate of distant metastases.
Hence, a prospective controlled trial is needed to
investigate the potential significance of targeted thera-
pies/combined radioimmunotherapy for EGFR positive
adenoid cystic carcinomas in a representative, homoge-
neous and untreated patient cohort. The ACCEPT
trial (Adenoidcystic carcinoma, Erbitux® and particle
therapy) is currently in preparation to answer these
questions.
Figure 4 Corresponding DVH; dose prescribed to the median
of CTV1; 100% := 66 Gy.
Figure 5 Follow-up contrast enhanced MRI 14 months post radioimmunotherapy: therapy-related changes: pterygoid muscles (a) and
cavernous sinus/left orbit (b).
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